Correlation between lncRNAs with human molecular chaperons in cancer immunopathogenesis and drug resistance
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Long non-coding RNAs (lncRNAs) interact with molecular chaperones to regulate cancer pathways and influence tumor immunity. Targeting this lncRNA-chaperone axis offers novel strategies for cancer diagnosis and treatment.
Area Of Science
- Cancer immunology
- Molecular biology
- Gene regulation
Background
- Cancer immunology research increasingly focuses on the interplay between long non-coding RNAs (lncRNAs) and molecular chaperones.
- lncRNAs are crucial regulators of gene expression, while molecular chaperones are vital for protein homeostasis and cellular stress responses.
Purpose Of The Study
- To explore the functional significance of the interaction between lncRNAs and molecular chaperones in cancer.
- To elucidate how this interaction influences oncogenic pathways and the tumor microenvironment.
- To identify potential therapeutic targets within the lncRNA-chaperone axis for cancer treatment.
Main Methods
- Investigating the molecular mechanisms by which lncRNAs interact with molecular chaperones.
- Analyzing the impact of these interactions on gene regulation and protein folding in cancer cells.
- Assessing the effects on immune cells within the tumor microenvironment.
Main Results
- lncRNA-chaperone interactions were found to significantly influence oncogenic pathways.
- These interactions affect both tumor cells and immune components within the tumor microenvironment.
- The lncRNA-chaperone axis represents a promising target for modulating anti-tumor immunity.
Conclusions
- The interaction between lncRNAs and molecular chaperones is a key determinant in cancer development and progression.
- Targeting the lncRNA-chaperone axis holds potential for developing innovative diagnostic and therapeutic strategies.
- Further research into specific lncRNA-chaperone associations could lead to personalized cancer therapies and improved treatment outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...